Background

Group B Streptococcus (GBS), also referred to as Streptococcus agalactiae, is an opportunistic pathogen that colonises the gastrointestinal and genitourinary tracts of up to 50% of healthy adults globally. GBS is estimated to cause 300,000+ cases of invasive neonatal disease (e.g. pneumonia, septicaemia and meningitis) globally, resulting in 90,000 deaths. GBS is also responsible for significant morbidity in pregnant women and is a growing problem in the elderly and immunocompromised adults.

We have established preclinical models closely mimicking GBS vaginal colonisation, invasive disease and mother-to-neonate vertical transmission. These models are a key pillar in the preclinical validation of our novel vaccine candidates.